BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months

Atezolizumab: trial readouts and FDA decisions

5 upcoming industry Phase 2/3 readout(s) in the next 90 days, 0 upcoming FDA event(s), 6 readout(s) in the last 180 days and 0 FDA event(s) in the last 12 months. Sponsors: Hoffmann-La Roche, Genentech, Inc., Nanjing Leads Biolabs Co.,Ltd, AbbVie, Biotheus Inc., Kahr Bio Australia Pty Ltd, Exelixis. Drug names come from ClinicalTrials.gov intervention names and FDA records, lightly normalised; one drug can appear under several names (code, generic, brand).

Upcoming trial readouts

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-11-30 est.P3Hoffmann-La RocheNCT03148418 A Study in Participants Previously Enrolled in a Genentech- and/or F. Hoffmann-La Roche Ltd-Sponsored Atezolizumab Study (IMbrella A)Canceractive not recruiting382
2026-11-30 est.P2Genentech, Inc.NCT04302025 A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)Non-small Cell Lung Canceractive not recruiting99
2026-12-28 est.P1/P2Nanjing Leads Biolabs Co.,LtdNCT06157827 A Clinical Trial of LBL-024 Combined With Etoposide and Platinum in Patients With Advanced Neuroendocrine CarcinomaAdvanced Neuroendocrine Carcinomarecruiting178
2026-12-31 est.P2Hoffmann-La RocheNCT05645692 A Study Evaluating Different Immunotherapies (LAG-3 and PD-1 With or Without TIGIT, Compared to PD-L1 Alone) in Participants With Untreated Locally Advanced MetUrothelial Canceractive not recruiting204
2027-01 est.P2/P3AbbVie ABBVNCT06109272 A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as aHepatocellular Carcinomaactive not recruiting89

Readouts, last 180 days

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-10-22P1/P2Hoffmann-La RocheNCT03533283 An Open-Label Phase lB/II Study of Glofitamab and Atezolizumab or Polatuzumab Vedotin in Adult Patients With Relapsed/Refractory B-Cell Non-Hodgkin's LymphomaNon-Hodgkins Lymphomacompleted211
2026-10-14 est.P3Hoffmann-La RocheNCT04770896 A Study of Atezolizumab With Lenvatinib or Sorafenib Versus Lenvatinib or Sorafenib Alone in Hepatocellular Carcinoma Previously Treated With Atezolizumab and BUnresectable Hepatocellular Carcinomaactive not recruiting557
2026-10 est.P1/P2Biotheus Inc.NCT06584071 A Study to Evaluate of PM8002 Combined With PM1009 in Patients With First-line HCCHCC; Liver Cancernot yet recruiting140
2026-09-30 est.P2Kahr Bio Australia Pty LtdNCT07235293 A Study to Test DSP107 in Combination With Atezolizumab in Comparison With Fruquintinib as a New Treatment for Colorectal Cancer.Colorectal Cancerrecruiting90
2026-07-22P3Hoffmann-La RocheNCT04543617 A Study of Atezolizumab With or Without Tiragolumab in Participants With Unresectable Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed FolloEsophageal Squamous Cell Carcinomacompleted760
2026-06-16P3Exelixis EXELNCT05425940 Study of XL092 + Atezolizumab vs Regorafenib in Participants With Metastatic Colorectal CancerColorectal Canceractive not recruiting901

Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA (openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score. Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP readout_calendar / fda_decisions. Not investment advice.